Literature DB >> 27268406

A framework for assessing outcomes from newborn screening: on the road to measuring its promise.

Cynthia F Hinton1, Charles J Homer2, Alexis A Thompson3, Andrea Williams4, Kathryn L Hassell5, Lisa Feuchtbaum6, Susan A Berry7, Anne Marie Comeau8, Bradford L Therrell9, Amy Brower10, Katharine B Harris11, Christine Brown12, Jana Monaco13, Robert J Ostrander14, Alan E Zuckerman15, Celia Kaye16, Denise Dougherty17, Carol Greene18, Nancy S Green19.   

Abstract

UNLABELLED: Newborn screening (NBS) is intended to identify congenital conditions prior to the onset of symptoms in order to provide early intervention that leads to improved outcomes. NBS is a public health success, providing reduction in mortality and improved developmental outcomes for screened conditions. However, it is less clear to what extent newborn screening achieves the long-term goals relating to improved health, growth, development and function. We propose a framework for assessing outcomes for the health and well-being of children identified through NBS programs. The framework proposed here, and this manuscript, were approved for publication by the Secretary of Health and Human Services' Advisory Committee on Heritable Disorders in Newborns and Children (ACHDNC). This framework can be applied to each screened condition within the Recommended Uniform Screening Panel (RUSP), recognizing that the data elements and measures will vary by condition. As an example, we applied the framework to sickle cell disease and phenylketonuria (PKU), two diverse conditions with different outcome measures and potential sources of data. Widespread and consistent application of this framework across state NBS and child health systems is envisioned as useful to standardize approaches to assessment of outcomes and for continuous improvement of the NBS and child health systems. SIGNIFICANCE: Successful interventions for newborn screening conditions have been a driving force for public health newborn screening for over fifty years. Organizing interventions and outcome measures into a standard framework to systematically assess outcomes has not yet come into practice. This paper presents a customizable outcomes framework for organizing measures for newborn screening condition-specific health outcomes, and an approach to identifying sources and challenges to populating those measures. Published by Elsevier Inc.

Entities:  

Keywords:  Long-term follow-up; Newborn screening; Outcomes; Quality improvement

Mesh:

Year:  2016        PMID: 27268406      PMCID: PMC4970906          DOI: 10.1016/j.ymgme.2016.05.017

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  28 in total

1.  Evaluating large-scale health programmes at a district level in resource-limited countries.

Authors:  Theodore Svoronos; Kedar S Mate
Journal:  Bull World Health Organ       Date:  2011-08-23       Impact factor: 9.408

2.  National evaluation of US newborn screening system components.

Authors:  Bradford L Therrell; W Harry Hannon
Journal:  Ment Retard Dev Disabil Res Rev       Date:  2006

3.  Status of newborn screening programs in the United States.

Authors:  Bradford L Therrell; Alissa Johnson; Donna Williams
Journal:  Pediatrics       Date:  2006-05       Impact factor: 7.124

4.  Financing newborn screening: sources, issues, and future considerations.

Authors:  Bradford L Therrell; Donna Williams; Kay Johnson; Michele A Lloyd-Puryear; Marie Y Mann; Lauren Raskin Ramos
Journal:  J Public Health Manag Pract       Date:  2007 Mar-Apr

5.  Standardizing newborn screening results for health information exchange.

Authors:  Swapna Abhyankar; Michele A Lloyd-Puryear; Rebecca Goodwin; Sara Copeland; John Eichwald; Bradford L Therrell; Alan Zuckerman; Greg Downing; Clement J McDonald
Journal:  AMIA Annu Symp Proc       Date:  2010-11-13

6.  Mortality among children with sickle cell disease identified by newborn screening during 1990-1994--California, Illinois, and New York.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  1998-03-13       Impact factor: 17.586

7.  Impact of hydroxyurea on clinical events in the BABY HUG trial.

Authors:  Courtney D Thornburg; Beatrice A Files; Zhaoyu Luo; Scott T Miller; Ram Kalpatthi; Rathi Iyer; Phillip Seaman; Jeffrey Lebensburger; Ofelia Alvarez; Bruce Thompson; Russell E Ware; Winfred C Wang
Journal:  Blood       Date:  2012-08-22       Impact factor: 22.113

8.  Mountain States Genetics Regional Collaborative Center's Metabolic Newborn Screening Long-term Follow-up Study: a collaborative multi-site approach to newborn screening outcomes research.

Authors:  Erica L Wright; Johan L K Van Hove; Janet Thomas
Journal:  Genet Med       Date:  2010-12       Impact factor: 8.822

9.  Exploring barriers to long-term follow-up in newborn screening programs.

Authors:  Timothy Hoff; Adrienne Hoyt; Brad Therrell; Maria Ayoob
Journal:  Genet Med       Date:  2006-09       Impact factor: 8.822

10.  Long-term follow-up after diagnosis resulting from newborn screening: statement of the US Secretary of Health and Human Services' Advisory Committee on Heritable Disorders and Genetic Diseases in Newborns and Children.

Authors:  Alex R Kemper; Coleen A Boyle; Javier Aceves; Denise Dougherty; James Figge; Jill L Fisch; Alan R Hinman; Carol L Greene; Christopher A Kus; Julie Miller; Derek Robertson; Joseph Telfair; Brad Therrell; Michele Lloyd-Puryear; Peter C van Dyck; R Rodney Howell
Journal:  Genet Med       Date:  2008-04       Impact factor: 8.822

View more
  7 in total

1.  Current priorities for public health practice in addressing the role of human genomics in improving population health.

Authors:  Muin J Khoury; Michael S Bowen; Wylie Burke; Ralph J Coates; Nicole F Dowling; James P Evans; Michele Reyes; Jeannette St Pierre
Journal:  Am J Prev Med       Date:  2011-04       Impact factor: 5.043

2.  Following Patients With Inborn Errors of Metabolism: What Do We Value and How Do We Know?

Authors:  Jeffrey P Brosco; Cynthia F Hinton
Journal:  Pediatrics       Date:  2021-07-15       Impact factor: 7.124

3.  Early access to biological neonatal screening: coordination among child care action programs.

Authors:  Beatriz Molina Carvalho; Waldomiro Roberto Tavares; Jéssica Batistela Vicente; Gabriel Zanin Sanguino; Adriana Moraes Leite; Maria Cândida de Carvalho Furtado
Journal:  Rev Lat Am Enfermagem       Date:  2020-05-11

4.  Early Check: translational science at the intersection of public health and newborn screening.

Authors:  Donald B Bailey; Lisa M Gehtland; Megan A Lewis; Holly Peay; Melissa Raspa; Scott M Shone; Jennifer L Taylor; Anne C Wheeler; Michael Cotten; Nancy M P King; Cynthia M Powell; Barbara Biesecker; Christine E Bishop; Beth Lincoln Boyea; Martin Duparc; Blake A Harper; Alex R Kemper; Stacey N Lee; Rebecca Moultrie; Katherine C Okoniewski; Ryan S Paquin; Denise Pettit; Katherine Ackerman Porter; Scott J Zimmerman
Journal:  BMC Pediatr       Date:  2019-07-17       Impact factor: 2.125

Review 5.  Outcomes in pediatric studies of medium-chain acyl-coA dehydrogenase (MCAD) deficiency and phenylketonuria (PKU): a review.

Authors:  Michael Pugliese; Kylie Tingley; Andrea Chow; Nicole Pallone; Maureen Smith; Alvi Rahman; Pranesh Chakraborty; Michael T Geraghty; Julie Irwin; Laure Tessier; Stuart G Nicholls; Martin Offringa; Nancy J Butcher; Ryan Iverson; Tammy J Clifford; Sylvia Stockler; Brian Hutton; Karen Paik; Jessica Tao; Becky Skidmore; Doug Coyle; Kathleen Duddy; Sarah Dyack; Cheryl R Greenberg; Shailly Jain Ghai; Natalya Karp; Lawrence Korngut; Jonathan Kronick; Alex MacKenzie; Jennifer MacKenzie; Bruno Maranda; John J Mitchell; Murray Potter; Chitra Prasad; Andreas Schulze; Rebecca Sparkes; Monica Taljaard; Yannis Trakadis; Jagdeep Walia; Beth K Potter
Journal:  Orphanet J Rare Dis       Date:  2020-01-14       Impact factor: 4.123

6.  Inequities in newborn screening: Race and the role of medicaid.

Authors:  Heeju Sohn; Stefan Timmermans
Journal:  SSM Popul Health       Date:  2019-10-07

7.  Two novel mutations in DNAJC12 identified by whole-exome sequencing in a patient with mild hyperphenylalaninemia.

Authors:  Mengting Li; Qi Yang; Sheng Yi; Zailong Qin; Jingsi Luo; Xin Fan
Journal:  Mol Genet Genomic Med       Date:  2020-06-10       Impact factor: 2.183

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.